The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma

International Journal of Cancer

Volumn 125, Issue 4, 2009, Pages 783-790

  Sitaram, Raviprakash T ^a   Cairney, Claire J ^b   Grabowski, Pawel ^a   Keith, W Nicol ^b   Hallberg, Bengt ^a   Ljungberg, Börje ^a   Roos, Göran ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cMyc; DJ 1; hTERT; Prognosis; Proliferation; Renal cell carcinoma; Telomere length

Indexed keywords

DJ 1 PROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY PAPILLA; KNOCKOUT GENE; MAJOR CLINICAL STUDY; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TELOMERE; UPREGULATION;

BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY NEOPLASMS; ONCOGENE PROTEINS; PLOIDIES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; S PHASE; SURVIVAL RATE; TELOMERASE; TELOMERE;

EID: 67650095406     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24335     Document Type: Article

References (54)

1. Kovacs M, Akhtar BJ, Beckwith P, Bugert P, Cooper CS, Delahunt B, Ebel JN, Fleming S, Medeiros LJ, Moch H, Reuter VE, Ritz E, et al. The Heidelberg classification of renal cell tumors. J Pathol 1997; 183:131-3.
2. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K, Murai M. Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 2005;16:928-33.
3. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer. Cell 2005; 7:263-73.
4. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997;231:509-13.
5. MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res 2003;63:6928-34.
6. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, Hanash SM. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 2001; 7:3328-35.
7. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, van Swieten JC, Brice A, van Duijn CM, Oostra B, Meco G, Heutink P. DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol Sci 2003;24:159-60.
8. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989;59:521-9.
9. Collins K, Mitchell JR. Telomerase in human organism. Oncogene 2002;21:564-79.
10. Meyerson M, Counter CM, Eaton E, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785-95.
11. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB, Cech TR. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277: 955-9.
12. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J. The RNA component of human telomerase. Science 1995;269:1236-41.
13. Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase catalytic subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998;58:1558-61.
14. Kyo S, Kanaya T, Takakura M, Tanaka M, Inoue M. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999; 80:60-3.
15. Nakano K, Watney E, McDougall JK. Telomerase activity and expression of telomerase RNA component and telomerase catalytic subunit gene in cervical cancer. Am J Pathol 1998;153:857-64.
16. Kanaya T, Kyo S, Takakura M, Ito H, Namiki M, Inoue M. hTERT is a critical determinant of telomerase activity in renal-cell carcinoma. Int J Cancer 1998;78:539-43.
17. Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002;21: 541-52.
18. Liu JP. Studies of the molecular mechanisms in the regulation of telomerase activity (Review). FASEB J 1999;13:2091-104.
19. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 1999;19:1-11.
20. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/ Akt signaling pathway is activated due to aberrant PTEN expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004;23:8571-80.
21. Wu K, Grandori M, Amacker N, Simon-Vermot A, Polack J, Lingner, Dalla-Favera R. Direct activation of TERT transcription by c-MYC. Nat Genet 1999;21:220-4.
22. Paradis V, Bieche I, Dargere D, Bonvoust F, Ferlicot S, Olivi M, Lagha NB, Blanche P, Benoit G, Vidaud M, Bedossa P. hTERT expression in sporadic renal cell carcinomas. J Pathol 2001;195:209-17.
23. Fan Y, Liu Z, Fang X, Ge Z, Ge N, Jia Y, Sun P, Lou F, Bjorkholm M, Gruber A, Ekman P, Xu D. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues. Clin Cancer Res 2005;11:4331-7.
24. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002;62:3876-82.
25. Kimura A, Ohmichi M, Kawagoe J, Kyo S, Mabuchi S, Takahashi T, Ohshima C, Arimoto-Ishida E, Nishio Y, Inoue M, Kurachi H, Tasaka K, et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004;23:4505-15.
26. Sobin LH, Wittekind CH, eds. International Union Against Cancer. UICC TNM classification of malignant tumours, 6th edn. New York: Wiley-Liss 2002:193-5.
27. Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971;28:1165-77.
28. Pfaffl MW. A new mathematical model for relative quantification in real time RT-PCR. Nucleic Acids Res 2001;29:2003-07.
29. Stock RS, Emrich T, Peters B, Jaeger V, Roessner A. Analysis of human telomerase reverse transcriptase mRNA (hTERT) expression in myxoid liposarcomas using LightCycler real-time quantitative reverse transcriptase-polymerase chain reaction. Electrophoresis 2001;22:1098-101.
30. Nielsen NH, Emdin SO, Cajander J, Landberg G. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene 1997;14:295-304.
31. Palmqvist R, Zhang A, Xu D, et al. hTERT gene copy number is not associated with hTERT RNA expression or telomerase activity in colorectal cancer. Int J Cancer 2005;116:395-400.
32. Cawthon RM Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30:e47.
33. Grabowski P, Hultdin M, Karlsson K, Tobin G, Åleskog A, Thunberg U, Laurell A, Sundström C, Rosenquist R, Roos G. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005; 105:4807-12.
34. Vindeløv LL, Christensen IJ, Engelholm SA, Guldhammer BH, Hojgaard K, Sorensen BL, Wolf H. Prognostic significance of DNA content in bladder cancer based on flow cytometric analysis of 249 transitional cell carcinomas. Cytometry 1995;22:93-102.
35. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-14.
36. Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. Biol Chem 1999;274:13085-90.
37. Kondo K, Yao M, Kobayashi K, Ota S, Yoshida M, Kaneko S, Baba M, Sakai N, Kishida T, Kawakami S, Uemura H, Nagashima Y, et al. PTEN/MMAC1/TEP1 mutations in human primary renalcell carcinomas and renal carcinoma cell lines. Int J Cancer 2001; 91:219-24.
38. Velickovic M, Delahunt B, McIver B, Grebe SK. Intragenic PTEN/ MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 2002;15:479-85.
39. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002;99:53-7.
40. Lovell M, Lott ST, Wong P, El-Naggar A, Tucker S, Killary AM. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. Cancer Res 1999;59: 2182-9.
41. Liu MY, Poellinger L, Walker CL. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 2003;63:2675-80.
42. Robb VA, Karbowniczek M, Klein-Szanto AJ, Henske EP. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol 2007;177:346-52.
43. Perera AD, Kleymenova EV, Walker CL. Requirement for the von Hippel-Lindau tumor suppressor gene for functional epidermal growth factor receptor blockade by monoclonal antibody C225 in renal cell carcinoma. Clin Cancer Res 2000;6:1518-23.
44. Hedberg Y, Ljungberg B, Roos G, Landberg G. Expression of cyclin D1. D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray. Br J Cancer 2003;88:1417-23.
45. Diegmann J, Tomiuk S, Sanjmyatav J, Junker K, Hindermann W, von Eggeling F. Comparative transcriptional and functional profiling of clear cell and papillary renal cell carcinoma. Int J Mol Med 2006;18:395-403.
46. Chen YT, Tu JJ, Kao J, Zhou XK, Mazumdar M. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma. Clin Cancer Res 2005;11:6558-66.
47. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang NJ, et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003;22: 6810-8.
48. Lipponen P, Eskelinen M, Syrjänen K. Expression of tumour-suppressor gene Rb, apoptosis-suppressing protein Bcl-2 and c-Myc have no independent prognostic value in renal adenocarcinoma. Br J Cancer 1995;71:863-7.
49. Segawa N, Gohji K, Azuma H, Iwamoto Y, Ohnishi K, Katsuoka Y. Telomerase activity in renal cell carcinoma by modified telomeric repeat amplification protocol assay. Int J Urol 2003;10:153-9.
50. Patel PH, Chadalavada RSV, Chaganti RSK, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20.
51. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005;11:1129-35.
52. Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, Yang L, Beal MF, Nishimura I, Wakamatsu K, Ito S, Takahashi R, Lu B. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 2005;102:13670-5.
53. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer-and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci USA 2006;103:15091-6.
54. Anderson CJ, Hoare SF, Ashcroft M, Bilsland AE, Keith WN. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 2006;25: 61-9.